October 8, 2020
💥🇺🇸#SRNE
Компания Sorrento Therapeutics подала в FDA заявку на получение разрешения на экстренное использование для своего экспресс-теста COVI-STIX для обнаружения нуклеокапсидного антигена вируса SARS-CoV-2 в образцах из носа пациентов.
Компания Sorrento Therapeutics подала в FDA заявку на получение разрешения на экстренное использование для своего экспресс-теста COVI-STIX для обнаружения нуклеокапсидного антигена вируса SARS-CoV-2 в образцах из носа пациентов.
December 23, 2020
⚡️💥🇺🇸#SRNE
Sorrento - нейтрализация Дельта штамма
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
Sorrento - нейтрализация Дельта штамма
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
July 21, 2021
⚡️💥🇺🇸#SRNE
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary Off-the-Shelf Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary Off-the-Shelf Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
August 2, 2021
⚡️💥🇺🇸#SRNE
Sorrento Mexico, Mexico Government Execute Memorandum of Understanding for Rapid Clinical Development of COVID-19 Vaccines
Sorrento Mexico, Mexico Government Execute Memorandum of Understanding for Rapid Clinical Development of COVID-19 Vaccines
August 3, 2021
August 4, 2021
⚡️💥🇺🇸#SRNE
Sorrento to Obtain Exclusive Rights in N and S Amer, Europe, Major Asian Countries, Certain Other Countries to Utilize Dyadic's C1 Technology
#DYAI Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic's Lead Cvid-19 Vaccine Candidate and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Sorrento to Obtain Exclusive Rights in N and S Amer, Europe, Major Asian Countries, Certain Other Countries to Utilize Dyadic's C1 Technology
#DYAI Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic's Lead Cvid-19 Vaccine Candidate and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
August 11, 2021
⚡️💥🇺🇸#SRNE
Sorrento Therapeutics объявляет о вступлении в опционное соглашение c Texas A&M University System по эксклюзивной лицензии на ингибиторы MPRO против SARS-CoV-2
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
Sorrento Therapeutics объявляет о вступлении в опционное соглашение c Texas A&M University System по эксклюзивной лицензии на ингибиторы MPRO против SARS-CoV-2
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
August 24, 2021
🇺🇸#SRNE #препараты
Sorrento представила серию ингибиторов, которые могут потенциально использоваться при лечении от ковида
Sorrento представила серию ингибиторов, которые могут потенциально использоваться при лечении от ковида
December 6, 2021
February 13, 2023